betaFeedback

WorksComputer Science

Continuous Cuffless Blood Pressure Estimation Using PPG From Methods to Clinical Translation

Abstract

Continuous blood pressure (BP) monitoring could improve hypertension management by capturing changes that intermittent cuff measurements miss. Photoplethysmography (PPG) is widely explored for cuffless BP estimation because optical sensors are inexpensive, wearable, and already present in many consumer and clinical devices. PPG, however, does not measure arterial pressure: BP is inferred from waveform characteristics or pulse timing, which also depend on vascular tone, arterial stiffness, sensor contact, motion, and individual physiology. This survey reviews PPG-based cuffless BP estimation along the full measurement chain, covering physiological mechanisms, waveform features, pulse arrival time (PAT), pulse transit time (PTT), machine-learning methods, datasets, calibration, validation, deployment, bias, and clinical translation. Studies are assessed by the strength of evidence they provide rather than by reported error alone, with particular attention to subject and temporal leakage, dataset imbalance, calibration dependence and drift, motion artifacts, and the gap between benchmark accuracy and reliable real-world measurement. The review finds that progress depends on more than better prediction algorithms. Future work should prioritize physiologically informed models, diverse longitudinal datasets, transparent reporting of calibration requirements and failure rates, stronger evaluation protocols, and studies that demonstrate practical value in clinical care.

Introduction

Blood pressure (BP) is central to cardiovascular risk assessment and to the diagnosis and treatment of hypertension [1], [2]. The World Health Organization estimates that 1.4 billion adults aged 30–79 had hypertension in 2024. Only about one in five of them, some 320 million people, had their BP under control, and close to half did not know they had the condition [3]. Figure 1 shows how this population divides between those who are unaware, diagnosed but untreated, treated without reaching control, and controlled. Most of the shortfall lies in detection and long-term management, not in the availability of effective drugs.

Approximate global hypertension status among adults aged 30–79

Figure 1. Approximate global hypertension status among adults aged 30–79, based on WHO estimates [3].

The cuff remains the clinical reference. It is supported by outcome evidence, measurement guidelines, and established validation protocols [4]–[8], but it samples BP only intermittently. Office and home readings capture a few moments of the day, and ambulatory monitoring, although denser, still depends on repeated inflation. That matters because BP follows a daily rhythm. In many people it falls by approximately 10–20% during sleep and rises again in the early morning, and non-dipping, reverse dipping, and an exaggerated morning rise have all been associated with increased cardiovascular risk [6]. Figure 2 illustrates this limitation: the three cuff readings do not capture the morning peak or nocturnal trough.

24-hour BP pattern showing nocturnal dipping and a morning rise

Figure 2. 24-hour BP pattern showing nocturnal dipping and a morning rise [6].

Cuffless monitoring aims to fill these gaps with sensors that can be worn continuously. PPG is a widely investigated candidate because optical sensors are inexpensive and already built into smartwatches, rings, smartphones, and clinical pulse oximeters [9]–[13].

PPG does not measure arterial pressure directly. It records blood-volume changes in peripheral tissue, and BP has to be inferred from the shape of that signal or from pulse arrival time (PAT) and pulse transit time (PTT). All of these also depend on arterial stiffness, vascular tone, autonomic activity, and individual physiology [14], [15], and the waveform itself changes with motion, temperature, sensor contact, and perfusion. The mapping from PPG to BP differs from person to person and drifts within a person over time.

Machine-learning and deep-learning models have reported low errors on public benchmarks, but benchmark performance alone does not establish generalizability. Accuracy depends on the population and BP range of the dataset, on signal quality, on how training and test data are separated, and on whether the model is calibrated to each user [16], [17]. Reported accuracy can be inflated when recordings from the same subject appear in both training and test sets, or because it is recalibrated against a cuff so often that it adds little to the cuff. Few commercial devices have been validated at all [18], and expert groups have argued that the standards used for cuff devices are not adequate for cuffless ones [19].

Several reviews already cover this field. El-Hajj and Kyriacou [20] and Qin et al. [21] catalogue machine-learning architectures by model family, Zhao et al. [10] survey sensing hardware, Charlton et al. [13] review wearable PPG for cardiovascular monitoring more broadly, and Islam et al. [22] pool validation results for commercial wearables. This survey differs by evaluating studies according to the strength of evidence supporting their claims. Cuffless BP estimation is evaluated as a measurement problem spanning physiology, signal processing, modeling, validation, and clinical translation.

The paper makes four contributions. It classifies studies by the strength of their evidence, from physiological plausibility to clinical utility. It interprets reported accuracy in light of subject independence, temporal separation, calibration, and BP-range coverage. It brings together the growing evidence on cross-dataset generalization, ambulatory performance, and commercial-device validation, which shows how far benchmark accuracy overstates real-world accuracy. Finally, it assesses newer directions, including physics-informed models, on-device inference, remote PPG, and federated and self-supervised learning, against the same criteria.

Section II outlines the estimation pipeline, and Sections III–V cover its physiological basis, waveform features, and estimation methods. Sections VI–XI examine how these methods are evaluated and where they fail. Section XII turns to clinical translation, Section XIII sets out research priorities, Section XIV states the limitations of this review, and Section XV concludes.

Overview of the PPG-Based Cuffless BP Pipeline

Most PPG-based systems share the processing chain in Figure 3 [9, 10, 21]. A wearable sensor records the PPG, which is filtered and cut into individual beats, with poor-quality segments discarded. Features are then extracted from each beat by hand or learned by a neural network. Because the PPG–BP relationship differs between people, the mapping is usually calibrated or personalized, and a regression or deep-learning model finally outputs SBP, DBP, or MAP.

Overview of a modern PPG-based cuffless blood pressure estimation pipeline

Figure 3. Overview of a modern PPG-based cuffless blood pressure estimation pipeline.

Errors introduced during acquisition or preprocessing can propagate through subsequent stages of the pipeline. Poor contact corrupts acquisition, filtering and segmentation can move the landmarks that features depend on, and model generalization is limited by the diversity of the training data and the calibration conditions used during development. The sections that follow take the stages in order, starting with the physiology that connects an optical signal to arterial pressure.

Physiological Mechanisms of Cuffless BP Estimation

PPG as an Optical Surrogate

PPG measures how much light tissue absorbs or reflects as its blood volume changes with each heartbeat [11, 12, 26]. The upper panel of Figure 4 shows where that light goes. Skin, bone, muscle, venous blood, and non-pulsatile arterial blood absorb a roughly constant amount; only the pulsatile arterial component varies from beat to beat, and it is typically a small fraction of the total. The signal is therefore modeled as

PPG signal components and characteristic waveform morphology

Figure 4. PPG signal components and characteristic waveform morphology. Reproduced from [27].

PPG(t)=DC+AC(t)(1)PPG(t) = DC + AC(t) \tag*{(1)}

where DCDC is the baseline (non-pulsatile) component and AC(t)AC(t) is the pulsatile arterial component.

The lower panel of Figure 4 shows the resulting waveform, divided into a systolic phase, when the vascular bed fills, and a diastolic phase, when it empties. Each pulse carries four landmarks: the pulse onset at the start of the upstroke, the systolic peak at maximum volume, the dicrotic notch associated with aortic valve closure, and the diastolic peak associated with waves reflected from the periphery. The notch is often weak or missing at the wrist. Pulse shape reflects cardiac ejection, vascular compliance, peripheral resistance, and wave reflection, but also sensor optics and local tissue properties [27, 28, 29]. Because the pulsatile part rides on a much larger baseline, anything that shifts the baseline, such as a change in perfusion or contact pressure, also changes the apparent pulse amplitude. Vasoconstriction, vasodilation, temperature, sympathetic activation, local compression, sensor displacement, and processing artifacts can all alter the waveform without any change in BP. PPG is best understood as an indirect surrogate: it carries information about BP, mixed with several confounders.

PAT, PTT, and PEP

Pulse-timing methods use the time the pulse wave needs to reach a peripheral site. Figure 5 separates the three intervals involved. The pre-ejection period (PEP) is the electromechanical delay between electrical activation, marked by the ECG, and the opening of the aortic valve. PTT is the time the pulse takes to travel between a proximal and a distal arterial site. PAT, usually measured from the ECG R-peak to a landmark on the distal PPG, spans both:

Figure 5. Conceptual distinction between PEP, PTT, and PAT. PAT includes the electromechanical delay represented by PEP in addition to vascular transit time, making it less specific to BP than idealized PTT.

PAT=PEP+PTT(2)PAT = PEP + PTT \tag*{(2)}

Measuring PTT directly requires two synchronized sensors at different arterial sites, which is difficult in a single wearable. PAT needs only an ECG and one PPG, but it is less specific to BP: PEP changes with contractility, stress, autonomic activity, and medication independently of vascular transit [14], [15], so a change in PAT can originate in the heart instead of the arteries.

Pulse Wave Velocity and Wave Reflection

PTT-based methods [14], [30]–[32] rely on the dependence of pulse wave velocity (PWV) on the elasticity of the arterial wall. Panel (a) of Figure 6 models the artery as an elastic tube, for which the Moens–Korteweg equation gives

Pulse wave propagation, wave reflection, and pressure amplification in the arterial tree

Figure 6. Pulse wave propagation, wave reflection, and pressure amplification in the arterial tree. Adapted from [14].

PWV=Eh2rρ(3)PWV = \sqrt{\frac{Eh}{2r\rho}} \tag*{(3)}

where EE is the arterial elastic modulus, hh the vessel wall thickness, rr the arterial radius, and ρ\rho the blood density. The same panel writes propagation in transmission-line form, with pressure traveling as P(x,t)=f(x±[LC(p)]−1/2t)P(x,t) = f(x \pm[LC(p)]^{-1/2}t), so that

PWV=1LC(p)(4)PWV = \frac{1}{\sqrt{LC(p)}} \tag*{(4)}

where LL is the blood inertance and C(p)C(p) the pressure-dependent arterial compliance per unit length [14]. Compliance falls as pressure rises, so higher BP gives faster propagation and a shorter PTT. That pressure dependence is what makes PTT informative. Its variation from one vessel and one person to another is what makes the relationship subject-specific, and arterial stiffness, vascular tone, aging, medication, disease, posture, and exercise all shift PWV independently of acute BP [15], [33], [34].

Panels (b) and (c) add two complications. In panel (b), the waveform at any point is the sum of a forward wave from ventricular ejection and a backward wave reflected from the microcirculation. Near the proximal end the two are separated by roughly twice the transit time; near the distal end they overlap. The same heartbeat thus produces differently shaped pulses at different sites, and reflection alters pulse shape and timing independently of absolute BP. Panel (c) shows that as the pulse travels from the central aorta to a peripheral artery, the systolic peak rises while diastolic pressure falls slightly, widening the pulse pressure, so a peripheral measurement is not a direct reading of central pressure. No single timing-to-BP conversion holds across individuals, which is why PTT-based estimation almost always needs calibration or personalization.

PPG Signal Morphology and Feature Representation

Feature-based methods summarize each pulse with a handful of measurements, such as systolic amplitude, upstroke slope, rise time, pulse width, pulse area, derivative peaks, augmentation-related indices, and dicrotic-notch timing, and feed them to a regression model [11], [28], [29]. The features are cheap to compute and easy to interpret, which suits wearable hardware. Each of them, however, depends on a landmark that something other than BP can move.

The features fall into four families, each tied to part of the physiology above. Amplitude and area features describe how much the vascular bed fills and so reflect perfusion and compliance. Timing features, including rise time, pulse width, and notch timing, describe how quickly it fills and empties and are linked to propagation. Shape features such as augmentation indices capture the contribution of reflected waves. Derivative features, taken from the first and second derivatives of the PPG, sharpen inflection points that are hard to locate in the raw waveform [28].

FeatureIntended meaningMajor risk
Systolic amplitudePulse volumeContact/optical variation
Upstroke slopeEjection and stiffnessMotion and filtering effects
Rise timeTransit-related behaviorLandmark instability
Pulse widthWaveform durationHeart-rate dependence
Dicrotic notchReflection/valve timingOften absent in wrist PPG
Derivative peaksMorphological detailNoise amplification

Table 1. Common PPG features and interpretation risks.

Table I pairs common features with their intended meaning and their main risk. Systolic amplitude reflects pulse volume but responds just as readily to contact pressure and optical coupling. Upstroke slope and rise time depend on precise landmark detection, which motion and filtering disturb. Pulse width varies with heart rate, the dicrotic notch is often absent at the wrist, and derivative peaks amplify noise. Wrist-worn sensors suffer most, because contact and motion change continuously. Filtering, smoothing, baseline correction, and beat rejection

make the signal look cleaner, but they can also shift timing landmarks or remove awkward segments, so the features a model sees may describe a better signal than the device actually records.

Taxonomy of Cuffless BP Estimation Methods

Figure 7 groups the estimation methods. The three upper branches differ in how the input is represented: handcrafted morphology, pulse timing, or representations learned by a deep network. Multimodal fusion and personalized or adaptive models build on these branches, and the dashed layer at the bottom marks validation, calibration, and evaluation design as concerns shared by every category.

High-level taxonomy of cuffless BP estimation approaches

Figure 7. High-level taxonomy of cuffless BP estimation approaches. Validation-aware design applies across all categories.

Feature-Based Regression

Classical methods apply linear regression, support vector regression, random forests, gradient boosting, or shallow neural networks to handcrafted PPG or ECG–PPG features [35, 36, 37, 38, 39]. They are interpretable and computationally light, but their accuracy is capped by feature quality, and they are sensitive to sensor artifacts, subject variability, and calibration choices. Ensembles such as random forests and gradient boosting cope with noisy or redundant features better than linear regression, at some cost in interpretability. Support vector regression needs careful scaling but performs well with small training sets, a useful property when most datasets contain few subjects. Under subject-independent evaluation, González et al. found that feature-based models did best on the two smaller benchmark datasets, whereas deep networks led only on the largest [40].

Deep Learning

Deep-learning methods learn representations directly from raw or transformed waveforms with convolutional, recurrent, LSTM, transformer, U-Net, or spectro-temporal architectures [20, 41, 42, 43, 44, 45, 46, 47, 48]. No single architecture has consistently demonstrated superior performance across datasets and evaluation settings. Convolutional networks are efficient and capture local shape but need extra machinery for the long-range dependencies that recurrent and transformer models handle directly, usually at higher computational and data cost. U-Net-style methods such as PPG2ABP reconstruct the full arterial waveform instead of a single SBP/DBP pair. This tends to produce physiologically plausible outputs but makes errors harder to express in the mmHg terms clinicians use [46].

Models also differ in how the waveform is presented to them. Some take the raw PPG, some add its derivatives, and some convert it into a time–frequency image, such as a spectro-temporal representation or a continuous wavelet transform, before a convolutional network [41], [49]. Zhang et al. compared seven such representations across several architectures [49], which treats the representation as a design choice in its own right; it deserves to be reported as carefully as the architecture. Greater capacity also means a greater risk of fitting dataset-specific artifacts, subject identity, or preprocessing choices, and the small number of subjects in most datasets makes that risk worse.

Multimodal, Personalized, and Physics-Informed Models

Multimodal approaches combine PPG with ECG, accelerometry, phonocardiography, demographic variables, or prior cuff readings. The extra inputs can improve robustness, but they add hardware and burden for the user. Personalized models reduce inter-subject variability by adapting to each person; Carlucci et al. reported that patient-specific fine-tuning reduced error by up to 64% [50]. Because such adaptation usually requires reference cuff readings, a personalized model’s accuracy means little without its calibration requirements.

Physics-informed models take a middle path between hand-built features and unconstrained networks. Sel et al. added a Taylor approximation of known, slowly varying cardiovascular relationships to the training of a neural network and reduced the amount of labeled data needed by about fifteen times on average, using bioimpedance signals [51]. The approach has not yet been tested on PPG at scale, but it shows how the physiology described earlier can constrain a model, so that the network does not have to rediscover it from data.

On-Device Deployment

Continuous monitoring is only practical if inference runs on the wearable itself, within the memory and energy budget of a microcontroller. Potail et al. demonstrated a TinyML pipeline for continuous BP estimation from PPG on resource-constrained hardware [52]. Burrello et al. combined hardware-aware neural architecture search with quantization to fit PPG-to-BP models onto the GAP8 ultra-low-power processor; every optimized model fit in memory, whereas the most accurate reference network on the largest dataset did not [53]. An extended version of that work reported up to 7.5 fewer parameters at comparable or lower error and estimated that processing energy alone would allow weeks of continuous monitoring on a small battery [50]. Khurana et al. examined practical factors such as sampling frequency for deep-learning-based estimation [54]. Compression changes a model, however, and an on-device model must be validated as deployed, at its actual sampling rate and numerical precision, not only in its full-precision form.

Emerging Directions: Remote PPG and Federated Learning

Remote photoplethysmography (rPPG) extracts a PPG-like signal from video of the face or skin and removes the contact sensor altogether. Schrumpf et al. applied BP models trained on contact PPG to rPPG from facial video and reported reduced but non-trivial accuracy, stating the performance drop explicitly [55]. rPPG inherits every calibration and dataset-shift problem of contact PPG and adds lighting, skin-tone-dependent signal quality, compression artifacts, and head motion.

Federated learning addresses a different obstacle: privacy rules make waveform data hard to pool across institutions. Brophy et al. trained a generative model for continuous arterial waveform estimation from PPG in a federated setting, in which simulated client devices share model updates instead of raw data [56]. Such training could reach larger and more diverse populations without centralizing sensitive recordings. Both approaches remain under evaluation, and current evidence is insufficient to establish improved BP accuracy.

Comparative Summary

Table 2 compares these approaches by input, main strength, main limitation, and calibration dependence. The approaches differ substantially in their calibration requirements, input signals, and evaluation conditions, which makes direct comparison of reported accuracy difficult. Pulse-timing and personalized methods rely on reference readings explicitly. Deep-learning methods are often presented as calibration-free, a claim that holds only under the evaluation conditions examined in the next section. The newer directions change how data are acquired, processed, or shared, but they leave the measurement problem itself in place: a remote, federated, or on-device model must meet the same validation requirements as any other.

ApproachTypical inputMain strengthMain limitationCalibration dependence
Feature-based regressionHandcrafted PPG or ECG–PPG featuresInterpretable, low computational costBounded by feature quality; sensitive to artifactsSensitive to calibration choices
Pulse timing (PAT/PTT)ECG and one or two PPG sitesPhysiological link to arterial stiffnessPEP, vascular tone, and aging confound timingGenerally requires calibration
Deep learningRaw or transformed waveformsCaptures nonlinear waveform patternsOverfitting; limited interpretabilityOften reported as calibration-free; vulnerable to leakage
Waveform reconstructionPPG mapped to the arterial waveformPhysiologically plausible output shapeErrors harder to express in mmHgDepends on evaluation design
Multimodal fusionPPG with ECG, accelerometry, PCG, or demographicsPotentially more robustDevice complexity and user burdenVaries by design
Personalized or adaptivePopulation model plus user dataReduces inter-subject variabilityRequires reference readingsExplicitly calibration-dependent
Remote PPGFacial or skin videoNo contact sensorLighting, skin tone, compression, and head motionInherits contact-PPG requirements
Federated trainingDistributed waveform dataLarger populations without pooling raw dataDoes not by itself adapt to new usersUnchanged by the training scheme
Physics-informedSensor data plus physiological modelLess labeled data; interpretable structureModel assumptions must hold for the userReduced, not removed
On-device (TinyML)Compressed versions of the aboveLow power; local processingAccuracy loss from compression; small memorySame as the source model

Table 2. Comparison of Cuffless BP Estimation Approaches.

Machine Learning Pitfalls

Cuffless BP models are usually scored by MAE, RMSE, ME, and SD. These metrics are meaningful only when supported by an appropriate experimental design. Several recurring issues can substantially affect the reported results.

A major concern is subject leakage. Long recordings are cut into many short, overlapping or adjacent windows [17], [57]. When windows from the same person end up in both the training and the test set, the model can recognize persistent subject-specific properties (vascular anatomy, sensor characteristics, individual physiology) instead of learning a relationship that holds for new people. The impact of subject leakage can be substantial. In a benchmark of public datasets, González et al. found that leaky random splits made models appear far better than subject-independent splits, while under subject-independent evaluation most models improved only modestly on a naive predictor that always outputs the training-set mean, and some did not beat it at all [40]. Windowing also inflates apparent dataset size, since many windows may come from few people, so studies should report the number of subjects, not only the number of windows, in each partition.

Figure 8 contrasts the two ways of partitioning such data. In a record-wise split, windows from every subject are spread across both sets, and the test set contains no new individual. In a subject-wise split, such as leave-one-subject-out or subject-grouped cross-validation, every window of a test subject is withheld from training. Subject-wise partitioning is the minimum requirement for any claim that a model works on new users.

Record-wise and subject-wise split diagrams

Figure 8. Record-wise and subject-wise partitioning of windowed recordings from four subjects (S1–S4). In (a), windows from every subject appear in both sets, allowing subject leakage; in (b), the test subject is never seen during training.

Temporal leakage is subtler. Neighboring windows from one recording share morphology, heart rate, and vascular state, so splitting them at random produces a test set much closer to the training data than any deployment would. Training on earlier portions of a recording and testing on later ones avoids the problem and gives a first look at how performance holds up over time. Leakage can also enter through preprocessing: normalization statistics, feature selection, or signal-quality thresholds computed on the full dataset carry information from the test set into training, so each of these steps should be fitted on the training data alone.

Imbalance is the third problem. Public datasets contain far more normotensive or stable samples than hypertensive or hypotensive ones, so a model can post a low average error while failing in exactly the ranges where treatment decisions are made. Evaluating only clean, motionless segments hides the effect of motion and low perfusion in the same way. Finally, a subject-wise split still tests generalization only within one dataset, where sensors, protocols, and populations are shared. External validation on independently collected data is the stronger test, and few studies report it. In all of these cases the reported error describes the test design as much as the model, which is why validation practice is the subject of the next section.

Validation: Evidence Types, Metrics, and Standards

Evidence in this field comes in several kinds, and they do not support the same conclusions. Table III lists the main types with what each contributes, what it supports, and its main limitation. Physiological and PTT/PAT studies explain why a signal may carry BP-related information but say nothing about device accuracy. Classical and deep-learning studies show algorithmic feasibility, but their results depend on the dataset split, feature quality, and overfitting. Dataset and validation papers make benchmarking possible, while leaving the realism of the data and the validation of cuffless devices unresolved.

Evidence typeTypical contributionWhat it supportsMain limitation
PPG physiologyExplains optical waveform morphology and fiducial featuresSupports interpretation of PPG-derived featuresDoes not establish BP accuracy
PTT/PAT theoryLinks pulse timing to vascular stiffness and pulse propagationSupports timing-based BP estimation mechanismsSensitive to PEP, tone, stiffness, and calibration
Classical MLUses engineered waveform and timing features for regressionDemonstrates algorithmic feasibilityStrongly affected by dataset split and feature quality
Deep learningLearns waveform representations from raw or transformed signalsCaptures nonlinear patternsRisk of overfitting and limited interpretability
Datasets and validationProvides waveform resources and evaluation standardsSupports benchmarking and clinical translation discussionDataset realism and cuffless validation remain unresolved

Table III. Major Evidence Categories in PPG-Based Cuffless BP Research

We order these kinds of evidence as a ladder with four tiers: physiological plausibility (a signal correlates with BP), algorithmic feasibility (a model reproduces BP on a specific dataset), validated measurement performance (the model generalizes under subject-independent, temporally separated, and calibration-transparent evaluation), and clinical utility (the resulting measurement changes a diagnostic or treatment decision safely). A low error on a retrospective database reaches the second tier and no further. It shows that an algorithm reproduces the reference labels of that database, not that the relationship holds for unseen subjects, sensors, or physiological states.

Representative Studies Positioned on the Evidence Ladder

Table IV places six representative studies on the ladder, covering feature-based regression, convolutional deep learning, waveform reconstruction, and recent 2026 work. They were chosen because each reports enough methodological detail to be positioned with confidence and because a single, unambiguous source for its reported error could be identified. All error values come from the cited papers; for Kachuee et al., the same values are also reported by two later independent papers [46], [58].

Kachuee et al. and Ibtehaz et al. draw on the same subject pool, the UCI Cuff-Less Blood Pressure Estimation Dataset, a 942-patient MIMIC-II subset compiled by Kachuee et al., so their results compare modeling approaches on identical data and say nothing about other populations [36], [46]. Kachuee et al. report a general, calibration-free model without a subject-independent split, which places the study at algorithmic feasibility [36]. Slapničar et al. use leave-one-subject-out evaluation and meet the subject-independence criterion for validated measurement performance, although their single-institution dataset leaves external validity untested [41]. For Ibtehaz et al., a later inspection of the published source code found that PPG2ABP splits overlapping 10-second windows into training and test sets at random, so windows from the same patient appear in both, a confirmed case of subject leakage [59]. Pan et al. and Mohammadi et al. do not report subject-independent splits, so despite their low errors both remain at algorithmic feasibility until independently replicated [47], [48]. Zhang et al. are the only group to add an external test: after training on a public dataset, they compared their model with an oscillometric cuff in a separate group of 26 participants [49]. That is stronger evidence than a retrospective split, although the external results are reported only as correlations.

The numbers in Table IV also show how reporting has drifted. The two earliest studies report SBP errors of roughly 9–11 mmHg, the most recent about 2 mmHg. The lowest errors, however, come from studies without a reported subject-independent split, and Mohammadi et al. do not fully disclose their dataset. Zhang et al. report external correlations of R=0.96R = 0.96 for SBP and R=0.74R = 0.74 for DBP. A high correlation shows that estimates move with the reference; it does not show that they agree with it in mmHg, which is what Bland–Altman analysis and the validation standards test. The decline in reported MAE from 2017 to 2025 should not be read as steady progress, because the studies differ in dataset, population, preprocessing, and validation protocol, and the study with confirmed leakage sits in the middle of the range. None of the six reaches clinical utility, since none reports an ambulatory or outcome-linked validation.

StudySignal / ModelDataset (subjects)Subject-independent?Reported performanceEvidence-ladder tier
Kachuee et al., 2017 [36]PPG + ECG (PAT); AdaBoostUCI/MIMIC-II; 942 subjectsNot reportedSBP 11.17 mmHg; DBP 5.35 mmHg (corroborated in [46], [58])Algorithmic feasibility
Slapničar et al., 2019 [41]PPG + derivatives; spectro-temporal CNNMIMIC-III; 510 subjectsYes; leave-one-subject-outSBP 9.43 mmHg; DBP 6.88 mmHgValidated measurement performance (single institution)
Ibtehaz et al., 2022 [46]PPG only; U-Net waveform reconstruction (PPG2ABP)UCI/MIMIC-II; 942 subjects (same source pool as Kachuee et al.)No; random-window split permits subject overlap [59]SBP 5.73 ± 9.16 mmHg; DBP 3.45 ± 6.15 mmHgAlgorithmic feasibility (leakage confirmed)
Pan et al., 2024 [47]PPG only; waveform reconstructionVitalDB (extended)Not reportedSBP 2.16 ± 1.53 mmHg; DBP 1.12 ± 0.59 mmHgAlgorithmic feasibility
Mohammadi et al., 2025 [48]PPG only; hybrid CNN–BiLSTM with attentionNot fully disclosedNot reported; 5-fold cross-validationSBP 1.88 mmHg; DBP 1.34 mmHgAlgorithmic feasibility
Zhang et al., 2026 [49]PPG only; CWT + CNNUCI Open BP Database; external validation on 26 participantsPartial; independent participant group used for external validationSource dataset: SBP 3.80 ± 5.02 mmHg; DBP 1.65 ± 2.70 mmHg. External validation: R=0.96R = 0.96 (SBP); R=0.74R = 0.74 (DBP)Algorithmic feasibility with limited external validation

Table IV. Representative Studies Positioned on the Evidence Ladder

Agreement and BP-Range Stratification

Summary statistics can hide the errors that matter clinically. Mean error can be small when positive and negative errors cancel, and MAE and RMSE average over all samples, so a poorly served subgroup barely moves them. Bland–Altman analysis instead plots the difference between a method and its reference [60]. Figure 9 shows a schematic example. The mean difference indicates systematic bias, and the limits of agreement, the mean difference ±1.96\pm1.96 standard deviations, show the range within which most errors fall. In the example, errors center near zero at normal BP but become increasingly negative at high BP. A device with this pattern underestimates the very readings that drive treatment and may be unsafe despite a low average error. Because public datasets contain more normal-range than hypertensive or hypotensive samples, careful studies report performance separately for low, normal, elevated, and high BP whenever the data allow [7, 24].

Schematic Bland–Altman plot

Figure 9. Schematic Bland–Altman plot. Errors are centered near zero at normal BP but become increasingly negative at high BP, a proportional underestimation that an average error would conceal.

Cuff-Based Validation Standards

The AAMI/ESH/ISO universal standard and ISO 81060-2 define how intermittent BP devices should be validated [7, 8], and the oscillometric devices that serve as reference for most cuffless studies are themselves well characterized [61]. These standards judge agreement in mmHg, commonly requiring a mean difference within approximately 5 mmHg and a standard deviation not exceeding approximately 8 mmHg for SBP and DBP, a more clinically meaningful criterion than percentage accuracy. Many algorithmic studies report only MAE, which cannot be checked against these criteria; reporting the mean error and its standard deviation as well costs nothing. ISO 81060-3 extends clinical investigation to continuous non-invasive devices, covering both trending and absolute-accuracy claims, but it explicitly does not assess motion artifacts [62]. None of these documents addresses everything a wearable cuffless device faces: continuous wear, calibration dependence, and sensitivity to posture and motion.

Cuffless-Specific Validation

Mukkamala et al. argued that the universal standard is inappropriate for cuffless devices and showed, with examples from the literature and simulations, that many accuracy studies use methods that can produce misleading conclusions [19]. IEEE 1708 covers wearable cuffless devices across measurement modes: short-term, long-term, snapshot, continuous, beat-to-beat, and BP variability [63, 64]. The European Society of Hypertension recommends validation tailored to device function and calibration [23], and Hu et al. call for frameworks that account for calibration-dependent operation and real-world use [24].

Table V turns these recommendations into a reporting list, giving for each item what should be reported, why it matters, and the risk when it is missing. The items fall into four groups: error statistics (ME and SD, MAE and RMSE, Bland–Altman analysis, BP-range stratification), data separation (subject-independent and temporally separated splits), calibration (protocol and time since calibration), and conditions of use (motion, posture, and failure rate). Leaving out any group hides a specific weakness, from accuracy inflated by leakage to accuracy that reflects only clean segments.

Figure 10 recasts the evidence ladder as five practical validation stages: retrospective benchmarks on curated waveforms, controlled laboratory validation, ambulatory validation in daily life, longitudinal testing of drift and recalibration, and clinical outcome and treatment-impact studies. Retrospective benchmarks are useful for development, but clinical adoption needs evidence from the later stages, and many published studies have not moved past the first.

Validation ladder for cuffless BP technologies

Figure 10. Validation ladder for cuffless BP technologies. Many studies remain at the retrospective benchmark stage, whereas clinical adoption requires real-world, longitudinal, and outcome-linked evidence.

Datasets and Generalization Limitations

Public waveform datasets have driven much of the progress in cuffless BP research, because they provide synchronized signals and reference labels at a scale few laboratories could collect. MIMIC-III, VitalDB, PulseDB, MIMIC-BP, and PhysioNet resources are the most widely used [17, 57, 65, 66, 69]. Table VI compares them with two datasets recorded outside intensive care. MIMIC-III contains about 30,000 ICU patients recorded at 125 Hz, VitalDB 6,388 surgical patients recorded at up to 500 Hz, and PulseDB 5,361 subjects and more than five million 10-s segments curated from those two sources. PulseDB and MIMIC-BP were built to standardize segment selection and labeling, which makes results comparable when studies share subjects and partitions, but the recordings still come from hospital patients. PPG-BP, by contrast, contains 219 seated participants aged 20 to 89 with cuff references, but only three 2.1-second fingertip segments per person [67]. Aurora-BP is the largest ambulatory resource we found: more than 1,000 participants wore wrist devices recording PPG, ECG, tonometry, and accelerometry, with reference readings taken in the laboratory and by an ambulatory cuff over 24 hours [68].

RequirementWhat should be reportedWhy it mattersRisk if missing
Mean error and SDBias and spread of error in mmHgAligns with BP validation conventionsAverage performance may be misleading
MAE and RMSEAbsolute and squared-error summariesQuantifies prediction error magnitudeLarge individual errors may be hidden
Bland–Altman analysisAgreement and limits of agreement across BP rangeReveals systematic bias and outliersUnsafe errors may be missed
BP-range stratificationError in low, normal, elevated, and high BP rangesTests clinically important rangesHypertension performance may be weak
Subject-independent splitNo subject overlap between training and testingPrevents identity leakageInflated benchmark accuracy
Temporal separationPrevents adjacent windows from crossing train/test setsAvoids correlation leakageUnrealistically low error
Calibration protocolInitial, repeated, or calibration-free designDefines true device dependencyCuff dependence may be hidden
Time since calibrationAccuracy after hours, days, or weeksTests driftShort-term accuracy may not persist
Motion and postureStatic, walking, exercise, sleep, and body positionTests wearable realismDevice may work only in ideal conditions
Failure rateRejected or unavailable readingsPrevents silent exclusion biasAccuracy may reflect only clean segments

Table V. Accuracy and validation requirements for cuffless BP studies.

DatasetTypical settingSubjectsSampling rateUseful signalsMain limitation
MIMIC-III Waveform DatabaseICU∼30,000\sim30{,}000 patients (10,282 in the clinically matched subset)125 HzECG, PPG, arterial BPICU population and care-context bias [65]
VitalDBOperating room6,388 surgical patientsUp to 500 HzMultiple vital signs and waveformsAnesthesia and OR-specific physiology [66]
PulseDBCurated benchmark from MIMIC-III/VitalDB5,361 subjects (5,245,454 10-s segments)125 HzPPG, ECG, arterial BP labelsInherits ICU/OR setting limitations [17]
PPG-BPSeated, clinical room219 subjects aged 20–89 (657 records)1 kHzFingertip PPG (2.1-s segments), cuff BPVery short single-session recordings [67]
Aurora-BPLaboratory and 24-h ambulatoryMore than 1,000 participantsDevice-dependentWrist PPG, ECG, tonometry, accelerometry, ambulatory cuffIntermittent cuff reference; single device family [68]
Other ambulatory wearable datasetsDaily lifeVaries by study; often smallDevice-dependent, commonly 25–100 HzPPG, accelerometry, cuff referencesRealistic deployment conditions but harder to collect and standardize

Table VI. Dataset considerations for cuffless BP estimation.

How much each subject contributes matters as much as how many subjects there are. Figure 11 shows how many subjects remain in PulseDB, MIMIC-III Matched, and VitalDB as the minimum number of segments required per subject increases. At the lowest threshold PulseDB holds about 5,000 usable subjects, roughly the sum of its two sources. VitalDB subjects then drop out quickly: the VitalDB curve falls below MIMIC-III Matched at about 400 segments per subject and approaches zero by 2,000, where PulseDB converges to MIMIC-III Matched at about 700 subjects. The subjects with long recordings, who tend to dominate windowed training sets, come mainly from the ICU. ICU and operating-room patients are monitored, often sedated or hemodynamically unstable, and recorded with clinical-grade sensors; a wearable must work during walking, sleep, exercise, temperature change, and variable contact. The reference labels raise the same issue, since invasive arterial lines are used only in critically ill, anesthetized, or surgical patients.

Subject coverage of PulseDB, MIMIC-III Matched, and VitalDB as the minimum number of segments per subject increases

Figure 11. Subject coverage of PulseDB, MIMIC-III Matched, and VitalDB as the minimum number of segments per subject increases. Reproduced from [17].

Evidence on Generalization

Several recent studies have measured what happens when models leave the data they were trained on. Weber-Boisvert et al. trained models on MIMIC and tested them on PPG-BP, and vice versa; in both directions the models lost nearly all predictive power. Features that correlated strongly with SBP in PPG-BP correlated weakly in MIMIC, and the two datasets differed significantly in 20 of 31 pulse features after adjustment for heart rate [70]. Moulaeifard et al. benchmarked deep models across datasets and found in-distribution performance to be an overly optimistic guide: without calibration, their best model reached 13.9/8.5 mmHg (SBP/DBP) in-distribution and 10.0–18.6/5.9–10.3 mmHg on external datasets. Errors tracked the difference in BP distributions between training and test data, and models trained on MIMIC generalized poorly [71]. In the ambulatory Aurora-BP data, Shen et al. reported mean absolute differences of about 14 mmHg for SBP and 10 mmHg for DBP, by day and by night [72]. These figures are several times the errors that dominate the benchmark literature. Strong performance on hospital data demonstrates algorithmic feasibility; it does not demonstrate readiness for ambulatory use.

Calibration, Personalization, and Drift

Most cuffless systems do not infer absolute BP from PPG or timing signals alone [14, 16, 73]. They use one or more cuff readings to map the measured signal onto the user’s BP. Calibration improves short-term accuracy but leaves the device partly dependent on a cuff, and the degree of that dependence is central to what the device can claim.

Why Personalization Is Often Needed

The relationship between PPG features, PAT or PTT, and BP varies with age, arterial stiffness, vascular geometry, medication, autonomic tone, sensor site, and local perfusion [14, 16]. Two people can share similar PPG features but have different BP, and one person’s relationship can shift between rest, stress, exercise, and temperature change. Whether a device uses one reference reading, several, or repeated recalibration defines what it actually measures, and the protocol belongs alongside the accuracy figures. The size of the effect is visible in benchmark data: Moulaeifard et al. report in-distribution

errors of 9.0/5.8 mmHg with subject-specific calibration against 13.9/8.5 mmHg without it [71].

Calibration-Free Claims

Calibration-free estimation removes the cuff altogether, but it is the hardest claim to validate, because the model must generalize across subjects, sensors, and physiological states without any personal reference. It is also the claim most exposed to leakage. If windows from one person appear in both training and testing, a model can look calibration-free while relying on characteristics of that person it has already seen; González et al. note that some earlier work effectively treated such leakage as a form of calibration [40]. Calibration-free results are credible only under strictly subject-independent, temporally separated evaluation.

Calibration Drift

Even a good calibration does not last indefinitely. Medication changes, disease progression, vascular remodeling, aging, posture, stress, temperature, sensor repositioning, and strap tightness can all alter PPG morphology or pulse timing without any change in central pressure. Figure 12 sketches the consequence. Error stays close to its day-0 value for the first days, then rises over weeks and months, and a study that measures accuracy only during the calibration session sees just the flat start of the curve. A drifting device keeps producing plausible numbers after its calibration has become invalid, which makes drift a safety problem as well as an accuracy problem. Validation should report error as a function of time since calibration, and the recalibration interval should be treated as a core device characteristic [23, 73].

Schematic illustration of calibration drift

Figure 12. Schematic illustration of calibration drift. Error measured shortly after calibration may not represent long-term performance.

Comparing Approaches to the Drift and Personalization Problem

The strategies proposed for personalization and drift are not interchangeable. Periodic recalibration against a cuff is the most direct and is implicit in most commercial designs, but it brings back the cuff, and its value depends on how often users actually recalibrate. Feature-level personalization adjusts a population model with a few subject-specific readings, which lightens the calibration burden but must still be evaluated on subjects not used for personalization. Transfer learning and domain adaptation adapt a population model to a new subject, sensor, or population with far less data than training from scratch. Self-supervised pretraining on large amounts of unlabeled PPG offers another route; Pillai et al.’s PaPaGei foundation model demonstrates this for PPG-based physiological signals in general, although its benefit for BP has not been evaluated directly [74]. Explicit drift detection, which treats drift as a condition to flag instead of a parameter to re-fit, has received little attention.

None of these strategies removes the need for transparent reporting. They differ in where the burden of adaptation falls, not in whether adaptation is needed. Table VII lists what should be reported for each calibration issue: the number and type of reference readings for initial calibration, the recalibration interval and trigger for repeated calibration, subject-independent external validation for calibration-free designs, error against time since calibration for drift, and the calibration and use conditions when physiological state changes.

IssueReasonReporting need
Initial calibrationAligns model output to individual BP levelNumber and type of reference readings
Repeated calibrationMaintains accuracy as physiology changesRecalibration interval and trigger
Calibration-free designAvoids cuff dependencySubject-independent external validation
Calibration driftSignal–BP relationship changes over timeError versus time since calibration
Physiological stateRest, stress, sleep, exercise, and posture alter signalsCalibration and use conditions

Table VII. Calibration issues in cuffless BP monitoring

Bias, Equity, and Optical Sensing Limitations

Because PPG is optical, its quality depends on skin and tissue properties, sensor wavelength, contact pressure, perfusion, and motion. Pulse-oximetry studies have documented errors associated with skin pigmentation [75, 76, 77]. For PPG itself the picture is mixed. Melanin absorbs strongly at the green wavelengths most wrist devices use, and several studies have reported larger heart-rate errors in darker skin [78], whereas Bent et al. found no significant effect of skin tone on heart-rate error across six commercial wearables [79]. Heart rate depends only on pulse timing, while BP estimation also relies on amplitude and shape, which may be more sensitive to optical attenuation. The evidence therefore points to a plausible risk for cuffless BP, not a demonstrated bias, and settling the question will take validation across diverse skin tones.

The make-up of training data creates a second source of bias. The main public datasets come from hospitalized adults, so models trained on them may not transfer to healthy users, ambulatory hypertensive patients, older adults, pregnant individuals, pediatric populations, or people with vascular disease, however large the dataset. Studies should report demographic and physiological descriptors (age, sex, BP range, health status, medication use, comorbidities, sensor site, and calibration protocol) where feasible and ethically appropriate, together with skin-tone or pigmentation-relevant variables where available, and should use them to test robustness, not to support unfounded biological assumptions.

Table VIII collects six sources of bias (skin and tissue optics, age and vascular stiffness, medication and disease, care setting, sensor site, and motion and posture), with how each affects cuffless BP, what should be reported, and the clinical risk when it is ignored. Several rows tie directly to mechanisms described earlier. Age and vascular stiffness change pulse wave velocity and waveform shape, so a model trained mostly on one age range may transfer poorly to another. Medication and disease alter vascular tone, heart rate, and BP dynamics, so a device can report misleading trends after a change in treatment. Wrist, finger, ear, and phone-based PPG differ in signal quality, and each fails in its own way.

Bias sourceHow it affects cuffless BPWhat should be reportedClinical risk
Skin and tissue opticsAlters PPG signal strength and morphologySkin tone or pigmentation-relevant descriptors when feasibleUneven accuracy across users
Age and vascular stiffnessChanges pulse wave velocity and morphologyAge range and vascular disease statusPoor transfer across age groups
Medication and diseaseAlters vascular tone, heart rate, and BP dynamicsMedication and comorbidity informationMisleading BP trends
Care settingICU/OR data differ from daily-life wearable useDataset source and acquisition contextBenchmark accuracy may not translate
Sensor siteWrist, finger, ear, and phone PPG differ in signal qualitySensor location and attachment methodSite-specific failure modes
Motion and postureCorrupts PPG and changes hydrostatic conditionsActivity and posture during measurementFailure during real-world use

Table VIII. Sources of Bias and Generalization Risk in Cuffless BP Estimation

Wearable Deployment Failure Modes

A wearable has to work in conditions that retrospective datasets rarely contain, and the move from cuff-based to contactless monitoring raises deployment questions beyond BP alone [80]. Walking, exercise, sleep movement, sweating, temperature change, sensor repositioning, and inconsistent strap tightness all degrade PPG quality [10, 11, 12], and they corrupt the very landmarks BP estimation depends on. Even for heart rate, the simplest PPG measurement, error during activity was about 30% higher than at rest across commercial devices [79].

Motion matters most because continuous monitoring is most valuable when the wearer is moving. An algorithm that discards most data during activity or sleep transitions fails exactly when continuous information is needed. Contact pressure causes a related problem: loose contact increases motion artifact, while excessive pressure alters local perfusion and can mimic a BP change when central pressure has not moved. Posture has a measurable effect as well. In a validation of a commercial optical bracelet, agreement with auscultation met ISO 81060-2 criteria when participants sat with the wrist at heart level, but the standard deviation of the error rose to about 10 mmHg lying down and about 12.5 mmHg standing [81]. Cold exposure, dehydration, and peripheral vascular disease further reduce PPG amplitude independently of central BP, and wrist, finger, ear, and phone-based sensors couple to tissue differently, so results from one site should not be assumed to hold at another.

Signal-quality assessment is the first line of defense. A signal-quality index computed from waveform morphology, spectral content, or an accelerometer can flag or correct corrupted segments before they reach the BP estimator. Pollreisz and TaheriNejad compared detection and removal strategies, from morphological heuristics to reference-signal and accelerometer-based methods, and found that no single technique performs well across all activity types [82]. Errors in BP estimation may have greater clinical consequences than errors in heart-rate estimation, because a beat that passes the quality filter with subtly distorted morphology can still yield a plausible but wrong BP value. Signal-quality assessment belongs in the reported estimation pipeline, together with the share of data it rejects.

A robust device has to be validated under its intended conditions of use, not only at rest. Table IX lists the conditions wearable studies should test. Resting seated measurement provides the baseline comparison with conventional devices; standing, walking or arm movement, exercise and recovery, sleep, and cold or low-perfusion states test robustness where PPG degrades; and repeated use over time tests drift and recalibration needs.

ConditionReason for inclusion
Resting seated postureBaseline comparison with conventional measurement
Standing postureTests hydrostatic and vascular changes
Walking or arm movementTests motion robustness
Exercise or recoveryTests BP increase and dynamic tracking
Sleep or supine restTests nocturnal monitoring feasibility
Cold or low-perfusion stateTests weak PPG signal conditions
Repeated use over timeTests drift and recalibration needs

Table IX. Real-World Conditions That Should Be Tested in Wearable Cuffless BP Studies

Clinical Translation

From Benchmark Accuracy to Clinical Meaning

Clinical usefulness depends on whether BP estimates remain valid as the user, sensor, physiology, environment, and calibration state change. Figure 13 draws the preceding sections together. Its upper row follows the chain from a wearable PPG signal to clinical use, and its lower row names the main risk at each stage: skin optics and sensor contact, motion artifact and low perfusion, vascular tone and PEP, calibration drift and subject leakage, dataset shift and unreported failures, and unclear thresholds with limited outcome evidence. A weakness at any stage can make an accurate benchmark result clinically unreliable.

Graphical summary of the survey

Figure 13. Graphical summary of the survey. PPG-based cuffless BP estimation is best understood as a measurement chain rather than a single regression task.

The evidence from commercial devices bears this out. A 2022 search of 205 commercial cuffless devices found that only 11 had undergone an independently validated testing and none had been tested under IEEE 1708 [18]. A meta-analysis of 16 validation studies covering 15 devices and 974 participants found pooled mean differences of 3.42 mmHg for SBP and 1.16 mmHg for DBP, but with very high heterogeneity (I2I^2 of 95% and 87%) and without assessing the spread of errors that ISO criteria require [22]. A small average bias, in other words, coexists with large and inconsistent errors across devices and studies.

Clinical decisions are also asymmetric in their risks. Underestimating high systolic BP may delay treatment, while overestimation causes unnecessary concern. A trend tracker, a home hypertension support tool, and a medication-titration system need different evidence. A trend tracker that reports relative changes for general wellness must show that its readings move in the right direction under everyday conditions. A home support tool that prompts users to confirm elevated readings with a cuff must detect elevated BP reliably and report how often it raises false alarms. A system used to adjust medication must agree with reference measurements in absolute mmHg across the hypertensive range, stay stable between calibrations, and be supported by outcome evidence. Continuous data may one day reveal nocturnal patterns, morning surge, and medication response, but the rules for interpreting them must be validated clinically, not borrowed from intermittent cuff thresholds.

Evidence Required at Each Stage

Good performance on a curated waveform dataset does not turn a model into a clinical measurement device. Table X pairs each stage of the validation ladder in Figure 10 with the evidence it needs, the question it answers, and the claim it supports. A retrospective benchmark shows whether an algorithm can estimate BP on existing data and supports only a feasibility claim. Controlled and ambulatory validation show whether the device works under standardized conditions and in daily life, longitudinal validation whether its accuracy holds, and only clinical outcome studies whether it improves care. A 2025 international review in JAMA Cardiology reached the same conclusion: cuffless devices are appealing but need validation before clinical deployment, with open concerns about accuracy, undertreatment or overtreatment, equitable access, privacy, and workflow integration [25]. The claim made for a device should match the stage of evidence actually behind it.

StageEvidence neededMain questionClaim supported
Retrospective benchmarkCurated waveform data with clear splitsCan the algorithm estimate BP on existing data?Feasibility
Controlled validationStandardized posture, activity, and BP-change testingDoes the device work under controlled conditions?Technical validation
Ambulatory validationDaily-life testing with realistic motion and sensor useDoes the device work outside the lab?Wearable-use validation
Longitudinal validationRepeated testing over time after calibrationDoes accuracy remain stable?Drift and recalibration evidence
Clinical outcome evaluationDiagnosis, treatment, adherence, or risk-prediction studiesDoes the device improve care?Clinical utility

Table X. Evidence pathway for clinical translation of cuffless BP technology.

Future Research Directions

Future progress will require stronger evidence in addition to further improvements in benchmark accuracy. Important gaps remain in longitudinal datasets, uncertainty estimation, require [22]. and standardized reporting. The first is data. Aurora-BP shows that large ambulatory collections with cuff references can be built and shared [68], but to our knowledge no public dataset yet follows participants over weeks to months with repeated reference measurements, several device types, and documented skin tone, which together are needed to study drift and bias. Such a benchmark should also ship with predefined subject-wise partitions so that results can be compared directly. The second is uncertainty. Models should report how confident they are in each estimate, for example as a prediction interval or a drift flag, so that readings taken under poor signal quality or after the calibration has degraded can be identified. Shen et al. have shown that conformal prediction can attach intervals with close to nominal coverage to ambulatory cuffless estimates [72]. The third is reporting. BP-range- and skin-tone-stratified error tables should be a condition of publication, much as CONSORT-style checklists are for clinical trials, and the pulse-oximetry experience shows why.

Several technical directions may help address these limitations. Physics-informed models that build the propagation and reflection mechanisms described earlier into learning have already reduced labeling needs in related signals [51] and could make failures easier to diagnose. Continual personalization, which updates a model as new weakly labeled data arrive from a user or sensor, offers a middle ground between calibration-free and fully individualized models. Multimodal sensing that fuses PPG with accelerometry, temperature, or bioimpedance on the device could address motion, contact pressure, and skin temperature at the source, at the cost of hardware complexity and power; on-device optimization of the kind reviewed earlier makes this increasingly practical.

Reporting should finally be complete enough for a reader to tell which tier of evidence a study reaches. Table XI lists the minimum information future studies should report: study

ItemRequired detail
PopulationAge, sex, health status, BP range
Sensor siteWrist, finger, ear, phone, or other
SignalsPPG only or multimodal inputs
Reference BPCuff, arterial line, or other source
CalibrationInitial, repeated, or calibration-free
Split designSubject-independent and temporal policy
Motion handlingInclusion, exclusion, and failure rate
MetricsMean error, SD, MAE, RMSE, stratified error
Deployment claimScreening, tracking, or clinical measurement

Table XI. Minimum reporting checklist for future studies.

population, sensor site, input signals, reference BP source, calibration approach, split design, motion handling and failure rate, error metrics, and the intended deployment claim, whether screening, tracking, or clinical measurement.

Limitations of This Survey

This review has three main limitations. It is a critical narrative review, not a registered systematic review. Retrieval was targeted and not exhaustively logged, so we cannot report the numbers of records identified, screened, and excluded, as a PRISMA-style review would, and readers cannot confirm that no significant contrary evidence was missed. We also did not pool reported accuracy values, because differences in dataset, population, calibration protocol, and train–test design would make a pooled estimate misleading. As a result, the review cannot say whether one family of methods reliably outperforms another, only which comparisons are well or poorly supported. The review emphasizes measurement validity when interpreting benchmark accuracy. This reflects the analytical framework adopted in this survey rather than a universally accepted prioritization. Our claims rest on the cited evidence, but broader normative positions, such as the view that the field should invest in validation infrastructure before further model refinement, are our assessment and not an established consensus. A systematic review with a registered protocol and strict inclusion criteria, limited to studies with transparent subject-independent evaluation and reproducible calibration, BP-range, and failure-rate reporting, would complement this work.

Conclusion

PPG-based cuffless BP monitoring is attractive because it could provide frequent, comfortable, and potentially continuous information that intermittent cuff readings miss. It remains, however, an unsolved measurement problem. PPG and pulse-timing signals are indirect surrogates for arterial pressure, and a low reported error does not rule out the confounders reviewed here. Where models have been tested outside their training data, in other datasets, in ambulatory use, or as commercial devices, errors have been several times larger than the benchmark literature suggests. For researchers, this means designing cuffless BP studies as measurement studies before presenting them as prediction studies. For clinicians and device developers, it means treating a calibrated trend estimate as something other than a diagnostic BP measurement and matching every claim to the evidence behind it.

With roughly four in five of the 1.4 billion adults with hypertension lacking adequate control [3], a device deployed on the strength of a retrospective benchmark alone could delay diagnosis or misdirect treatment and widen the very gap it was meant to close. Clinical readiness depends not only on benchmark MAE, but also on whether the complete measurement chain remains reliable across users, sensors, time, and real-world conditions. Current evidence therefore supports PPG-based cuffless BP estimation as a promising research direction, while further validation is required before dependable clinical use can be established.

References

References

  1. [1]W. B. Kannel, “Blood pressure as a cardiovascular risk factor: Prevention and treatment,” JAMA, vol. 275, no. 20, pp. 1571–1576, 1996.pubmed.ncbi.nlm.nih.gov/8622248
  2. [2]P. K. Whelton et al., “2017 ACC/AHA/PfA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults,” J. Am. Coll. Cardiol., vol. 71, no. 19, pp. e127–e248, 2018.
  3. [3]World Health Organization, “Global report on hypertension 2025: High stakes, turning evidence into action,” Geneva, Switzerland, 2025.
  4. [4]P. Muntner et al., “Measurement of blood pressure in humans: A scientific statement from the American Heart Association,” Hypertension, vol. 73, no. 5, pp. e35–e66, 2019.DOI
  5. [6]E. O’Brien et al., “European Society of Hypertension position paper on ambulatory blood pressure monitoring,” J. Hypertens., vol. 31, no. 9, pp. 1731–1768, 2013.DOI
  6. [7]G. S. Stergiou et al., “A universal standard for the validation of blood pressure measuring devices: AAMI/ESH/ISO collaboration statement,” J. Hypertens., vol. 36, no. 3, pp. 472–478, 2018.
  7. [8]ISO 81060-2:2018, “Non-invasive sphygmomanometers – Part 2: Clinical investigation of intermittent automated measurement type,” International Organization for Standardization, 2018.DOI
  8. [9]T. Tamura and M. Huang, “Cuffless blood pressure monitor for home and hospital use,” Sensors, vol. 25, no. 3, art. no. 640, 2025.DOI
  9. [10]L. Zhao et al., “Emerging sensing and modeling technologies for wearable and cuffless blood pressure monitoring,” npj Digit. Med., vol. 6, art. no. 93, 2023.DOI
  10. [11]J. Allen, “Photoplethysmography and its application in clinical physiological measurement,” Physiol. Meas., vol. 28, no. 3, pp. R1–R39, 2007.pubmed.ncbi.nlm.nih.gov/17322588
  11. [12]Y. Sun and N. Thakor, “Photoplethysmography revisited: From contact to noncontact, from point to imaging,” IEEE Trans. Biomed. Eng., vol. 63, no. 3, pp. 463–477, 2016.DOI
  12. [13]P. H. N. Charlton, P. A. Kyriacou, J. Mant, V. Marozas, P. Chocienczyk, and J. Alastyruev, “Wearable photoplethysmography for cardiovascular monitoring,” Proc. IEEE, vol. 110, no. 3, pp. 355–381, 2022.DOI
  13. [14]R. Mukkamala et al., “Toward ubiquitous blood pressure monitoring via pulse transit time: Theory and practice,” IEEE Trans. Biomed. Eng., vol. 62, no. 8, pp. 1879–1901, 2015.DOI
  14. [15]R. A. Payne, C. N. Symeonides, D. J. Webb, and S. R. J. Maxwell, “Pulse transit time measured from the ECG: An unreliable marker of beat-to-beat blood pressure,” J. Appl. Physiol., vol. 100, no. 1, pp. 136–141, 2006.pubmed.ncbi.nlm.nih.gov/16141378
  15. [16]J. E. Sharman et al., “Cuffless blood pressure monitoring: Promises and challenges,” Hypertension, vol. 75, no. 5, pp. 1139–1146, 2020.
  16. [17]W. Wang, P. Mohseni, K. L. Kilgore, and L. Najafizadeh, “PulseDB: A large, cleaned dataset based on MIMIC-III and VitalDB for benchmarking cuff-less blood pressure estimation methods,” Front. Digit. Health, vol. 4, art. no. 1090854, 2023.DOI
  17. [18]J. Cox, K. Louka, A. P. Avolio, I. Tan, and M. Butlin, “Are commercial cuffless blood pressure devices being validated?” J. Hypertens., vol. 40, no. e-Suppl. 1, p. e104, 2022.DOI
  18. [19]R. Mukkamala, M. Yavarimanesh, K. Natarajan, J.-O. Hahn, K. G. Kyriakoulis, A. P. Avolio, and G. S. Stergiou, “Evaluation of the accuracy of cuffless blood pressure measurement devices: Challenges and proposals,” Hypertension, vol. 78, no. 5, pp. 1161–1167, 2021.DOI
  19. [20]C. El-Hajj and P. A. Kyriacou, “A review of machine learning techniques in photoplethysmography for the non-invasive cuff-less measurement of blood pressure,” Biomed. Signal Process. Control, vol. 58, art. no. 101870, 2020.DOI
  20. [21]C. Qin, X. Wang, G. Xu, and X. Ma, “Advances in cuffless continuous blood pressure monitoring technology based on PPG signals,” BioMed Res. Int., vol. 2022, art. no. 8094351, 2022.DOI
  21. [22]S. M. S. Islam, C. K. Chow, R. Daraybaygikhotbehsa, N. Subedi, J. Rawstorn, T. Tegene, C. Karmakar, M. U. Siddiqui, G. Lambert, and R. Maddison, “Wearable cuffless blood pressure monitoring devices: A systematic review and meta-analysis,” Eur. Heart J. Digit. Health, vol. 3, no. 2, pp. 323–337, 2022.DOI
  22. [23]G. S. Stergiou et al., “European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices,” J. Hypertens., vol. 41, no. 12, pp. 2074–2087, 2023.DOI
  23. [24]J.-R. Hu et al., “Validating cuffless continuous blood pressure monitoring devices,” Cardiovasc. Digit. Health J., vol. 4, no. 1, pp. 9–20, 2023.DOI
  24. [25]E. Yang et al., “Cuffless blood pressure measurement devices – International perspectives on accuracy and clinical use: A narrative review,” JAMA Cardiol., vol. 10, no. 6, pp. 624–631, 2025.
  25. [26]M. Nitzan, A. Romem, and R. Koppel, “Pulse oximetry: Fundamentals and technology update,” Med. Devices (Auckl.), vol. 7, pp. 231–239, 2014.DOI
  26. [27]J. Park, H. S. Seok, S.-S. Kim, and H. Shin, “Photoplethysmogram analysis and applications: An integrative review,” Front. Physiol., vol. 12, art. no. 808451, 2022.DOI
  27. [28]M. Elgendi, “On the analysis of fingertip photoplethysmogram signals,” PLoS One, vol. 7, no. 10, art. no. e47097, 2012.pubmed.ncbi.nlm.nih.gov/22845812
  28. [29]W.-H. Lin, X. Li, G. Li, and F. Chen, “Investigating the physiological mechanisms of the photoplethysmogram features for blood pressure estimation,” Physiol. Meas., vol. 41, no. 4, art. no. 044003, 2020.DOI
  29. [30]C. C. Y. Poon and Y.-T. Zhang, “Cuff-less and noninvasive measurements of arterial blood pressure by pulse transit time,” in Proc. IEEE EMBS, 2006, pp. 5877–5880.pubmed.ncbi.nlm.nih.gov/17281597
  30. [32]X. Ding, B. P. Yan, Y.-T. Zhang, J. Liu, N. Zhao, and H. K. Tsang, “Pulse transit time based continuous cuffless blood pressure estimation,” Sci. Rep., vol. 7, art. no. 11554, 2017.DOI
  31. [33]H. Gesche, D. Grosskurth, G. Kuchler, and A. Patzak, “Continuous blood pressure measurement by using the pulse transit time: Comparison to a cuff-based method,” Eur. J. Appl. Physiol., vol. 112, pp. 309–315, 2012.DOI
  32. [34]X. Ding and Y.-T. Zhang, “Pulse transit time technique for cuffless unobtrusive blood pressure measurement: From theory to algorithm,” Biomed. Eng. Lett., vol. 9, no. 1, pp. 37–52, 2019.DOI
  33. [35]M. Kachuee, M. M. Kiani, H. Mohammadzade, and M. Shabany, “Cuffless high-accuracy calibration-free blood pressure estimation using pulse transit time,” in Proc. IEEE ICAS, 2015, pp. 1006–1009.DOI
  34. [36]M. Kachuee, M. M. Kiani, H. Mohammadzade, and M. Shabany, “Cuffless blood pressure estimation algorithms for continuous health-care monitoring,” IEEE Trans. Biomed. Eng., vol. 64, no. 4, pp. 859–869, 2017.DOI
  35. [37]H. Shin and S. D. Min, “Feasibility study for the non-invasive blood pressure estimation based on PPG morphology,” BioMed Eng. OnLine, vol. 16, art. no. 10, 2017.DOI
  36. [38]M. Radha et al., “Estimating blood pressure trends and the nocturnal dip from photoplethysmography,” Physiol. Meas., vol. 40, no. 2, art. no. 025006, 2019.DOI
  37. [39]J. Shao et al., “An optimization study of estimating blood pressure models based on pulse arrival time for continuous monitoring,” J. Healthc. Eng., vol. 2020, art. no. 4252985, 2020.
  38. [40]S. González, W.-T. Hsieh, and T. P.-C. Chen, “A benchmark for machine-learning based non-invasive blood pressure estimation using photoplethysmogram,” Sci. Data, vol. 10, art. no. 149, 2023.DOI
  39. [41]G. Slapničar, N. Mlakar, and M. Lustrek, “Blood pressure estimation from photoplethysmogram using a spectro-temporal deep neural network,” Sensors, vol. 19, no. 15, art. no. 3420, 2019.DOI
  40. [42]C. El-Hajj and P. A. Kyriacou, “Cuffless blood pressure estimation from PPG signals and its derivatives using deep learning models,” Biomed. Signal Process. Control, vol. 70, art. no. 102984, 2021.DOI
  41. [43]M. Panwar, A. Gautam, D. Biswas, and A. Acharyya, “PP-Net: A deep learning framework for PPG-based blood pressure and heart rate estimation,” IEEE Sensors J., vol. 20, no. 17, pp. 10000–10011, 2020.DOI
  42. [44]Y.-H. Li, L.-N. Harfiya, K. Purwandari, and Y.-D. Lin, “Real-time cuffless continuous blood pressure estimation using deep learning model,” Sensors, vol. 20, no. 19, art. no. 5606, 2020.
  43. [45]T. Athaya and S. Choi, “An estimation method of continuous noninvasive arterial blood pressure waveform using photoplethysmography: A U-Net architecture approach,” Sensors, vol. 21, no. 5, art. no. 1867, 2021.DOI
  44. [46]N. Ibtehaz et al., “PPG2ABP: Translating photoplethysmogram signals to arterial blood pressure waveforms using fully convolutional neural networks,” Bioengineering, vol. 9, no. 11, art. no. 692, 2022.
  45. [47]J. Pan et al., “Robust modelling of arterial blood pressure reconstruction from photoplethysmography,” Sci. Rep., vol. 14, art. no. 30333, 2024.DOI
  46. [48]H. Mohammadi, B. Tarvirdizadeh, K. Alipour, and M. Ghamari, “Cuffless blood pressure monitoring via PPG signals using a hybrid CNN-BiLSTM deep learning model with attention mechanism,” Sci. Rep., vol. 15, art. no. 22229, 2025.
  47. [49]H. Zhang, X. Hu, X. Zhang, Z. Chen, Y. Liang, and G. Wang, “A comparative study of signal representation methods and deep learning architectures for PPG-based cuffless blood pressure estimation,” Sensors, vol. 26, no. 9, art. no. 2847, 2026.DOI
  48. [50]F. Carlucci, G. Pollo, X. Wang, M. Poncino, E. Macii, L. Benini, S. Vinco, A. Burrello, and D. Jahier Pagliari, “End-to-end automated deep neural network optimization for PPG-based blood pressure estimation on wearables,” arXiv:2604.10117, 2026.arxiv.org/abs/2604.10117
  49. [51]K. Sel, A. Mohammadi, R. I. Pettigrew, and R. Jafari, “Physics-informed neural networks for modeling physiological time series for cuffless blood pressure estimation,” npj Digit. Med., vol. 6, art. no. 110, 2023.DOI
  50. [52]K. S. Potail, Y. R. Thota, and T. Nikouvin, “TinyML-based continuous blood pressure monitoring from PPG signals for resource-constrained devices,” in Proc. IEEE Comput. Soc. Annu. Symp. VLSI (ISVLSI), 2026.
  51. [53]A. Burrello, F. Carlucci, G. Pollo, X. Wang, M. Poncino, E. Macii, L. Benini, and D. Jahier Pagliari, “Optimization and deployment of deep neural networks for PPG-based blood pressure estimation targeting low-power wearables,” arXiv:2409.07485, 2024.arxiv.org/abs/2409.07485
  52. [54]V. Khurana, A. M. Pamidi, B. B. Joshi, G. B. Relde, R. R. Goutha, R. Bajpai, S. Kumar, and A. Khan, “Practical optimization of deep learning models for cuffless blood pressure estimation from photoplethysmography,” Physiol. Meas., vol. 47, no. 8, 2026.DOI
  53. [55]F. Schrumpf, P. Frenzel, C. Aust, G. Osterhoff, and M. Fuchs, “Assessment of non-invasive blood pressure prediction from PPG and rPPG signals using deep learning,” Sensors, vol. 21, no. 18, art. no. 6022, 2021.DOI
  54. [56]E. Brophy, M. De Vos, G. Boylan, and T. Ward, “Estimation of continuous blood pressure from PPG via a federated learning approach,” Sensors, vol. 21, no. 18, art. no. 6311, 2021.arxiv.org/abs/2102.12245
  55. [57]I. Sanches et al., “MIMIC-BP: A curated dataset for blood pressure estimation,” Sci. Data, vol. 11, art. no. 1233, 2024.DOI
  56. [58]D. Wang, X. Yang, X. Liu, S. Fang, L. Ma, and L. Li, “Photoplethysmography based stratification of blood pressure using multi-information fusion artificial neural network,” in Proc. IEEE/CVF Conf. Computer Vision and Pattern Recognition Workshops (CVPRW), 2020.DOI
  57. [59]S. Mehta, N. Kwatra, M. Jain, and D. McDuff, “Examining the challenges of blood pressure estimation via photoplethysmogram,” Sci. Rep., vol. 14, art. no. 18318, 2024.DOI
  58. [60]J. M. Bland and D. G. Altman, “Statistical methods for assessing agreement between two methods of clinical measurement,” Lancet, vol. 1, no. 8476, pp. 307–310, 1986.pubmed.ncbi.nlm.nih.gov/2868172
  59. [61]J. E. Sharman et al., “Automated ‘oscillometric’ blood pressure measuring devices: How they work and what they measure,” J. Hum. Hypertens., vol. 37, pp. 93–100, 2023.DOI
  60. [62]ISO 81060-3:2022, “Non-invasive sphygmomanometers – Part 3: Clinical investigation of continuous automated measurement type,” International Organization for Standardization, 2022.
  61. [63]IEEE Std 1708-2014, “IEEE standard for wearable cuffless blood pressure measuring devices,” IEEE, 2014.
  62. [64]IEEE Std 1708a-2019, “IEEE standard for wearable cuffless blood pressure measuring devices – Amendment 1,” IEEE, 2019.
  63. [65]A. E. W. Johnson et al., “MIMIC-III, a freely accessible critical care database,” Sci. Data, vol. 3, art. no. 160035, 2016.DOI
  64. [66]H.-C. Lee and C.-W. Jung, “VitalDB, a high-fidelity multi-parameter vital signs database in surgical patients,” Sci. Data, vol. 9, art. no. 279, 2022.DOI
  65. [67]Y. Liang, Z. Chen, G. Liu, and M. Elgendi, “A new, short-recorded photoplethysmogram dataset for blood pressure monitoring in China,” Sci. Data, vol. 5, art. no. 180020, 2018.DOI
  66. [68]B. Mieloszyk et al., “A comparison of wearable tonometry, photoplethysmography, and electrocardiography for cuffless measurement of blood pressure in an ambulatory setting,” IEEE J. Biomed. Health Inform., vol. 26, no. 7, pp. 2864–2875, 2022.DOI
  67. [69]A. L. Goldberger et al., “PhysioBank, PhysioToolkit, and PhysioNet: Components of a new research resource for complex physiologic signals,” Circulation, vol. 101, no. 23, pp. e215–e220, 2000.pubmed.ncbi.nlm.nih.gov/10851218
  68. [70]G. Weber-Boiser, B. Gosselin, and F. Sandberg, “Intensive care photoplethysmogram datasets and machine-learning for blood pressure estimation: Generalization not guaranteed,” Front. Physiol., vol. 14, art. no. 1126957, 2023.DOI
  69. [71]M. Moulaeifard, P. H. Charlton, and N. Strodthoff, “Generalizable deep learning for photoplethysmography-based blood pressure estimation: A benchmarking study,” arXiv:2502.19167, 2025.
  70. [72]Z. Shen et al., “Conformal prediction quantifies wearable cuffless blood pressure with certainty,” Sci. Rep., vol. 15, art. no. 26697, 2025.DOI
  71. [73]G. S. Stergiou et al., “Cuffless blood pressure measuring devices: Review and statement by the ESH Working Group,” J. Hypertens., vol. 40, no. 8, pp. 1449–1460, 2022.
  72. [74]A. Pillai, D. Spathis, F. Kawsar, and M. Malekzadeh, “PaPaGei: Open foundation models for optical physiological signals,” in Proc. Int. Conf. Learning Representations (ICLR), 2025.arxiv.org/abs/2410.20542
  73. [75]P. E. Bickler, J. R. Feiner, and J. W. Severinghaus, “Effects of skin pigmentation on pulse oximeter accuracy at low saturation,” Anesthesiology, vol. 102, no. 4, pp. 715–719, 2005.pubmed.ncbi.nlm.nih.gov/15791098
  74. [76]M. W. Sjoding et al., “Racial bias in pulse oximetry measurement,” N. Engl. J. Med., vol. 383, no. 25, pp. 2477–2478, 2020.DOI
  75. [77]A. Fawzy et al., “Racial and ethnic discrepancy in pulse oximetry and delayed identification of treatment eligibility among patients with COVID-19,” JAMA Intern. Med., vol. 182, no. 7, pp. 730–738, 2022.DOI
  76. [78]J. Fine, K. L. Branan, A. J. Rodriguez, T. Boonya-ananta, Ajmal, J. C. Ramella-Roman, M. J. McShane, and G. L. Coté, “Sources of inaccuracy in photoplethysmography for continuous cardiovascular monitoring,” Biosensors, vol. 11, no. 4, art. no. 126, 2021.DOI
  77. [79]B. Bent, B. A. Goldstein, W. A. Kibbe, and J. P. Dunn, “Investigating sources of inaccuracy in wearable optical heart rate sensors,” npj Digit. Med., vol. 3, art. no. 18, 2020.DOI
  78. [80]P.-K. Man et al., “Blood pressure measurement: From cuff-based to contactless monitoring,” Healthcare, vol. 10, no. 10, art. no. 2113, 2022.DOI
  79. [81]J. Sola, A. Vybornova, S. Fallet, E. Polychronoulou, A. Wurzner-Ghajarzadeh, and G. Wuerzner, “Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure,” Sci. Rep., vol. 11, art. no. 20644, 2021.DOI
  80. [82]D. Dollreiss and N. Taherinejad, “Detection and removal of motion artifacts in PPG signals,” Mobile Netw. Appl., vol. 27, no. 2, pp. 728–738, 2022.

Paper details

vlnc:W_z7pb7uwd
Version
v1 · latest
Published
Fresh — added to the Hub within the last 30 days
Added
License
CC BY 4.0
Usage

views · 0

downloads · 0

A view counts once per browser per day, a download each time the PDF is requested.

  • Computer Science

Not recorded for this paper

View statement
Looking for related papers…
Contents